Table 2 Drugs under scrutiny for the treatment/anticipation of CKD [41]
From: Review on kidney diseases: types, treatment and potential of stem cell therapy
Action/Mechanism | Drugs |
|---|---|
Blockade of renin | Aliskiren |
Inhibition of TGF-b–mediated Fibrosis | Pirfenidone |
Activation of over 250 cytoprotective genes, with protective activity on immune-mediated inflammation | Bardoxolone methyl |
Inhibition of CCL2 (also called MCP-1) | Bindarit |
Inhibition of ET-1–mediated arterial vasoconstriction, glomerular hypertension, increased proteinuria, and interstitial fibrosis | ET-1 antagonist |
Restoration of heparane sulphate component of basement membrane | Sulodexide |